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Abstract 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for which there 
is no cure. The early primary symptom of AD is the decline of memory ability, which 
gradually develops into complete dementia. Type 2 diabetes mellitus (T2DM) is an 
important risk factor of AD; and mimetics of the incretin hormone GLP-1 developed 
to treat diabetes are being tested as a novel therapeutic strategy for AD. In the present 
study, we reported for the first time the neuroprotective effects of a novel GLP-1/GIP 
dual agonist DA5-CH that activates the incretin hormone GLP-1 and GIP receptors in 
the APP/PS1 transgenic AD mouse model. We found that: (1) DA5-CH administration 
effectively improved working-memory and long-term spatial memory of 9-month-old 
AD mice in Y-maze and Morris water maze tests; (2) DA5-CH also reduced 
hippocampal amyloid senile plaques and phosphorylated tau protein levels; (3) 




potentiation; (4) DA5-CH up-regulated the levels of p-PI3K and p-AKT growth factor 
kinases and prevented excessive activation of p-GSK3β in the hippocampus of 
APP/PS1 mice. Therefore, the neuroprotection of DA5-CH in alleviating cognitive 
impairments and pathological damages might be associated with the improvement of 
hippocampal synaptic plasticity and activation of the PI3K/AKT signaling pathway. 
We propose that DA5-CH may be beneficial for the treatment of AD patients, 
especially those with T2DM or hyperglycemia. 
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Alzheimer’s disease (AD) is a chronic neurodegenerative disorder. The early primary 
symptom of AD is the decline of memory ability, which gradually develops into 
mental decline, and complete dementia in the end (Selkoe, 2001). As the population in 
the industrial nations reach higher life expectancies, the number of AD cases will 
increase continually to around 131 million by 2050 (Herrera et al., 2016). The typical 
neuropathological characteristics in the AD brain include high density of senile 
plaques, intracellular neurofibrillary tangles (NFTs) and neuronal death (Medina and 
Avila, 2013; Moreth et al., 2013). The main components of senile plaques are 
neurotoxic amyloid- (Aprotein. NFTs are formed by excessively phosphorylated 
tau protein and the number of NFTs in the brain is closely associated to the severity of 
dementia and can result in impairment of hippocampal synaptic plasticity (Batool et 
al., 2016; Tong et al., 2015) and learning and memory in wild type rats and transgenic 
mice (Paul and Magda, 2009). Unfortunately, effective AD treatment is still lacking to 
this day.  
According to recent reports, type 2 diabetes mellitus (T2DM), another degenerative 




2005; Hoyer, 2004; Luchsinger et al., 2004; Perry et al., 2007). A 1.5–2.5 fold 
increased risk of dementia has been reported in the T2DM (Strachan et al., 2011). 
Both AD and T2DM influence each other and share several common pathological 
characteristics including abnormalities in insulin level, insulin receptor and glucose 
metabolism. It is reported that Acan competitively bind to and inhibit neuronal 
insulin receptors in early-onset familial AD, while the neuronal insulin receptor can 
be desensitized in late-onset sporadic AD which is similar to those caused by T2DM. 
Further, insulin resistance has been linked to the increases of A and inflammatory 
agents in the human brain (Craft, 2007; Hoyer, 2004; Li and Hölscher, 2007). These 
researches support the hypothesis that the disorder of insulin signaling in the brain is 
associated with the occurrence of AD and other neurodegenerative diseases. Thus, a 
probable new strategy for the AD treatment is to regulate and normalize the insulin 
signaling system in the brain by activation of neuronal growth factor receptors and 
insulin-like receptors. Interestingly, Glucagon-like protein 1 (GLP-1), an incretin 
hormone used for the treatment of T2DM (Lovshin and Drucker, 2009), and its 
mimetics also have protective effects in animal models of AD (Hölscher, 2016; 
McClean and Holscher, 2014a). And a first pilot study with GLP-1 analogue 
liraglutide has shown beneficial effects in AD patients (Gejl et al., 2016). 
Glucose-dependent insulinotropic polypeptide (GIP), another incretin hormone, also 
shows neuroprotective effects in modulating neurotransmitter release, LTP formation, 
and protecting synapses (Faivre et al., 2011; Faivre et al., 2012). Furthermore, GLP-1 
analogues and GIP analogues have shown neuroprotective effects in AD mouse 
models, and this offers a new hope for the treatment of AD (Duffy and Hölscher, 2013; 
Faivre and Hölscher, 2013; Hölscher, 2014). 
Recently, a GLP-1/GIP Dual-Agonist-5 (DA5-CH), a novel protease-resistant 
GLP-1/GIP dual agonist, has been designed to treat AD or Parkinson’s disease. 
DA5-CH not only activates the GLP-1 receptor but also the sister incretin GIP 
receptor. Similar dual agonists have been developed to treat diabetes (Finan et al., 




treating diseases of the CNS. Since separate application of GLP-1 analogue and GIP 
analogue has shown beneficial effects on the neuroprotection (Duffy and Hölscher, 
2013; Faivre and Hölscher, 2013; Hölscher, 2014), the activation of both GLP-1 and 
GIP receptors with the unimolecular dual agonist may be a superior strategy for 
protecting neurons against AD-like insults.  
 
2. Materials and Methods 
2.1 Animals and drugs 
A total of sixty 9-month-old APPswe /PS1dE9 (APP/PS1) transgenic mice (half male 
and half female) and wild type (WT) C57BL/6J (C57) nest control mice (half male 
and half female) were ordered from Chinese Academy of Medical Sciences (Beijing, 
China). The mice were fed in an animal house with independent air supply system. 
The temperature of the animal room was maintained at 20℃-25℃, with 12 h light -12 
h dark cycle and sufficient food and water supply. All animal handling and procedure 
were carried out according to the guidelines of the Shanxi Committee on Ethics of 
Animal Research. The dual agonist DA5-CH was gotten from Chinapeptides Ltd 
(Shanghai, China). The purity of the peptide (95%) was confirmed by reversed-phase 
HPLC and characterised using matrix assisted laser desorption/ionisation time of 
flight (MALDI-TOF) mass spectrometry. The drug was stored in -80˚C and dissolved 
in saline before the experiments. 
All of the mice were divided into the following four groups: WT+Saline, 
WT+DA5-CH, APP/PS1+Saline and APP/PS1+DA5-CH. DA5-CH was dissolved in 
saline and injected intraperitoneally at a dose of 10 nmol/kg per day. In the control 
group, the same volume of saline was given. Behavioral tests were performed 28 days 
after drug application. 
Antibodies against p-PI3Kp85, PI3Kp85, p-Akt (ser473), Akt, p-GSK3β (Y216), 
GSK3β were purchased from Abcam, Inc. (Cat #: ab182651, ab189403, ab81283, 




bought from Biolegend (Cat #:803015, USA). The antibody to p-tau (AT8) was 
purchased from Thermo Scientific (Cat #:QE217252, USA). Anti-Rabbit IgG, 
Anti-mouse IgG, Mouse Anti-β-actin, CY3- Anti-mouse IgG, RIPA Lysate, BCA 
Protein Assay Kit, DAPI staining solution and Anti-fluorescence decay agent were 
from Boster (Wuhan, China). 
 
2.2 Behavioral tests 
2.2.1 Open field test 
To examine the locomotor activity and exploratory behavior of mice, open field test 
was used at first. Before the experiment, the animals had a 30 min of adaptation in the 
laboratory. The open field (40㎝×40㎝×40㎝) was divided into 16 equal size 
squares, in which 4 squares in the middle were defined as central area and the rest as 
peripheral area. Each mouse was placed individually in the apparatus from the center 
for 5 min and the total distance, as well as the percentage of time in center, was 
recorded by Smart 3.0 software system (Panlab, Spain) (Kovalenko et al., 2014). The 
apparatus was cleaned with 70% ethanol before each test. 
 
2.2.2 Y-maze test 
After open field test, the mice were subjected to a spontaneous alteration test in 
Y-maze to assess the spatial working memory of mice. The maze was made of three 
30 cm long, 7 cm high, 15 cm wide arms, with a triangular joint region in the central 
area. In the experiment, each mouse was placed in the central triangle region, and the 
mouse was allowed to explore freely the open arms for 8 min. The total arm entries 
and arm order was recorded by Smart 3.0 software system. A correct spontaneous 
alternation was defined as continuously entering 3 different arms. The percentage of 
correct alteration was calculated (Hritcu et al., 2007; Yamada et al., 1996). 
 
2.2.3 Spatial water maze and reversal water maze tests 
The spatial learning and memory of mice was tested using Morris water maze 




cm; high, 50 cm) and a small escape platform (diameter, 12 cm) in the pool. The tap 
water was injected into the pool, with a temperature of 22±2℃. The escape platform 
was submerged 1 cm beneath the water surface and placed in the center of one 
quadrant. The test includes two phases, acquisition trial and probe trial. The 
acquisition phase lasted for five training days (days 1–5) for the mice to search for the 
underwater platform located at the first quadrant according to the cues on the inner 
wall of the pool. When the mice climbed onto the platform or the time reached 1 min, 
the records stopped. The swimming traces of mice were monitored by a cameral right 
above the pool and the escape latencies were automatically recorded by Ethovision 
3.0 software system (Noldus Information Technology, the Netherlands). In the probe 
trial on the day 6, the platform was removed from the pool, and animals were allowed 
to swim freely for 1 min. The frequency of platform crossing and the swimming time 
in the target quadrant (the first quadrant) were recorded. After the classical MWM test 
finished, reversal water maze test was performed to examine the cognitive flexibility 
of mice. The platform was moved to the opposite quadrant (the third quadrant), and 
mice were placed into the water for similar four days acquisition trials and one day 
probe trial as mentioned above (Shang et al., 2016). In visible platform test, the 
platform was elevated 1cm above the water level and the mice were placed into two 
randomly selected quadrants. Swimming time to target was recorded. 
 
2.3  In vivo hippocampal L-LTP recording 
Considering the close correlation between the long term spatial memory and the 
synaptic plasticity in the hippocampus, (Clements et al., 1993), we observed 
hippocampal long-lasting LTP by recording excitatory postsynaptic potentials 
(fEPSPs) in the CA1 region after finishing MWM tests. The mice, under the 
anesthetization with urethane (i.p. 1.5 g/kg, Sigma, UK), were placed in a stereotaxic 
apparatus (RWD Life Science, China). The skin was cut open to expose the skull, and 
a binding stimulating/recording electrode (Sequim, WA, USA) was inserted into the 
CA1 region of hippocampus through a small hole drilled on the skull. The two tips of 




radiatum of the CA1 region, respectively. Basic synaptic transmission was observed 
for 30 min, with stable fEPSPs under test stimulation. Then, short term synaptic 
plasticity was observed at first by recording paired-pulse facilitation (PPF) with two 
paired test stimuli. The percentage of PPF ratio (fEPSP2/fEPSP1) was calculated. To 
induce long lasting L-LTP, three sets of high-frequency stimulation (HFS) with an 
interval of 5 min were delivered to the Schaffer collateral after PPF recording. Then, 
the fEPSPs under test stimulation were recorded for at least 180 min after HFS. A 
biological signal amplifier (Chengdu Instruments Ltd, China) was applied to record 
and analyze the obtained data. The percentage change of fEPSP slop at different time 
points after HFS was compared. 
 
2.4 Immunofluorescence staining 
Immunofluorescence experiments were performed to examine the distribution of Aβ 
plaques and phosphorylated tau protein in the hippocampus. After in vivo L-LTP 
recording, the brain of the mice were removed and fixed with paraformaldehyde for 
24 h, after that the tissue was transferred to 30％ sucrose solution. The brain was 
frozen to -80℃ and sectioned with freezing microtome (LEICA, CM1850, Germany ) 
at a thickness of 30 μm. Sections were transferred to PBS, blocked with normal goat 
serum (Solarbio, Beijing, China), followed by adding the primary antibody, second 
antibody, and DAPI. The Aβ plaque and phosphorylated tau protein were observed by 
confocal laser scanning microscopy (OLYMPUS, FV1200, Japan). The area 
percentage of anti-Aβ (6E10) or anti-p-tau (AT8) immunopositive particles in at least 
three hippocampal slices per mouse was calculated with the software Image-Pro Plus 
6.0.  
 
2.5 Western blotting  
The hippocampal tisue of mouse were isolated and homogenized in tissue protein 
extraction reagent, and a BCA Protein Assay Kit (Boster, Wuhan, China) was used to 
measure protein concentration. Taking out 50 μg of protein from each sample and 




proteins on the gels were transferred onto PVDF membranes and the membranes were 
incubated with a primary antibody overnight at 4℃, followed by a secondary 
antibody reaction for 2 h. The optical density of the target strip (p-PI3K, t-PI3K, 
p-AKT, t-AKT, p-GSK3β and t-GSK3β) was analyzed by using a gel image 
processing system (Alpha View SA, USA). 
 
2.6 Statistics   
All data in the study were represented as mean ± standard error of mean (S.E.M.). 
Statistical packages including SPSS 16.0 and SigmaPlot 12.3 were used for statistical 
analyses. The data from acquisition trial phases in MWM tests and in vivo 
hippocampal L-LTP were analyzed using three-way repeated measure analysis of 
variance (ANOVA). Two-way ANOVA was used to analyze other data. A statistical 
value of P＜0.05 was considered as significant. 
 
3. Results  
3.1 DA5-CH did not affect the locomotor and exploratory behaviors of APP/PS1 
and WT mice 
In Open-field test, the spontaneous behavior of WT and APP/PS1 mice was similar to 
each other. The total running distances of the mice in WT+Saline, WT+DA5-CH, 
APP/PS1+Saline and APP/PS1+DA5-CH were 1282.85 ± 89.51 cm, 1114.40 ± 96.04 
cm, 1158.11 ± 182.33 cm, and 1259.28 ± 125.81 cm, respectively. The ratio of time 
spent in the center were 1.99 ± 0.29％, 2.00 ± 0.27％, 1.79 ± 0.33％, and 1.88 ± 
0.38％, respectively. The two-way ANOVA statistical analysis did not show any 
significant main effects in total distance covered by the animals (APP/PS1: F(1, 43) <1; 
DA5-CH treatment: F(1, 43) <1; APP/PS1 by DA5-CH interaction: F(1, 43) =1.222, 
P >0.05; Fig. 1A) and the ratio of time spent in the center (APP/PS1: F(1, 43) <1; 
DA5-CH treatment: F(1, 43) <1; APP/PS1 by DA5-CH interaction: F(1, 43) <1; Fig. 1B). 




mice were not impaired, and DA5-CH did not affect the locomotor and exploratory 
performance of APP/PS1 and WT mice. 
 
3.2 DA5-CH improved the working memory of APP/PS1 mice 
In Y maze test, two-way ANOVA revealed that neither APP/PS1 nor DA5-CH 
treatment had significant effects on the total arm entries (APP/PS1: F(1, 33) =1.033, 
P >0.05; DA5-CH treatment: F(1, 33) <1; APP/PS1 by DA5-CH interaction: F(1, 33) <1; 
Fig. 2A). However, there were significant main effects of APP/PS1 and DA5-CH 
treatment in the percentage of right alternation (APP/PS1: F(1, 33) =15.704, P < 0.001; 
DA5-CH treatment: F(1, 33) =13.911, P < 0.001; APP/PS1 by DA5-CH interaction: F(1, 
33) =13.644, P < 0.001; Fig. 2B). The percentage of right alternation in the mice of 
APP/PS1+Saline group (52.13 ± 2.47％, P < 0.001) had a significant decrease 
compared to that in WT+Saline group (69.92 ± 2.01％), while the percentage in 
DA5-CH treated APP/PS1 transgenic mice had a significant improvement (69.38 ± 
2.47％, P < 0.001), very close to the value in the normal control group. These results 
indicate that the working memory, not general motor ability, of APP/PS1 transgenic 
mice in Y-maze was seriously impaired, which could be improved by DA5-CH 
treatment.  
 
3.3 DA5-CH ameliorated the spatial cognition deficits of APP/PS1 transgenic 
mice in classical MWM test. 
Fig. 3A and 3B show the results of the acquisition phase for each group of mice in the 
MWM for 5 consecutive days. The mean escape latency in the four groups was 
decreased after each training day (F(4, 148) =17.012, P < 0.001). Significant main 
effects existed in group WT vs. APP/PS1 (F(1, 38) =5.839, P < 0.05) and in group saline 
vs. DA5-CH treatment (F(1, 38) =6.643, P < 0.05) on escape latency. There was a 
significant interaction between APP/PS1 and DA5-CH treatment (F(1, 38) =7.573, P < 
0.05). The escape latencies in the APP/PS1+Saline group were significantly higher on 




(48.77 ± 4.44 s, P < 0.01), and day 5 (45.46 ± 4.14 s , P < 0.01) compared to the 
values in the WT+Saline group on the corresponding training days 2-5 (37.48 ± 3.42 s, 
35.40 ± 3.27 s, 31.62 ± 3.63 s and 26.89 ± 3.38 s). Importantly, DA5-CH treatment 
significantly decreased the values in APP/PS1 mice, being 33.44 ± 4.05 s (P < 0.01), 
35.79 ± 4.39 s (P < 0.05) and 31.61 ± 4.11 s (P < 0.05) on day 3-5, respectively, 
significantly lower than that of the APP/PS1+Saline group. This indicates that chronic 
treatment with DA5-CH can significantly ameliorate spatial learning in APP/PS1 
mice. 
The spatial memory retrieval of mice was assessed by the probe trial. Two-way 
ANOVA showed that APP/PS1 and DA5-CH treatments had significant main effects 
on the percentage of swimming time in target quadrant (APP/PS1: F(1, 38) =12.561, P 
< 0.01; DA5-CH treatment: F(1, 38) =9.940, P < 0.01; APP/PS1 by DA5-CH interaction: 
F(1, 38) =12.417, P < 0.01) and the number of platform crossings (APP/PS1: F(1, 38) 
=6.955, P < 0.05; DA5-CH treatment: F(1, 38) =4.618, P < 0.05; APP/PS1 by DA5-CH 
interaction: F(1, 38) =4.720, P < 0.05). As shown in Fig. 3C, the percentage of 
swimming time in target quadrant in the APP/PS1 mice (27.30 ± 2.40%, P < 0.01) 
was far lower compared to the WT mice (34.10 ± 1.10%), but not in the DA5 treated 
APP/PS1 mice (33.60 ± 2.00%, P < 0.05). We also counted the number of platform 
crossings (Fig. 3D) in the four groups of mice and found similar results. The 
frequency of platform crossings in APP/PS1+Saline group (1.00 ± 0.28) was 
significantly lower than that in WT+Saline group (3.00 ± 0.34, P < 0.01), while the 
frequency in DA5-CH treated APP/PS1 transgenic mice was higher (2.00 ± 0.29, P < 
0.01), indicating that the spatial memory disorder in the AD mice could be effectively 
ameliorated by the chronic treatment with DA5-CH.  
To exclude the impact of motor ability and vision impairments on the above tests, we 
performed a visible platform test after the probe trial. We found that there was no 
significant difference in the escape latency between all groups (20.77 ± 2.63 s, 20.13 
± 2.67 s, 22.21 ± 3.10 s, 25.26 ± 2.47 s, respectively, APP/PS1: F(1, 38) =1.297, P > 




the visible test, suggesting that the prolongation of the escape latency, decrease of the 
percentage of time in target quadrant and frequency of platform crossing in APP/PS1 
mice is not due to the differences in vision and swimming ability, but is due to the 
impairments in spatial learning and memory function. 
 
3.4 DA5-CH protected the relearning ability and cognitive flexibility of APP/PS1 
transgenic mice in a reversal MWM test 
In the reversal MWM test, as shown in the Fig. 4A and 4B, the times (escape 
latency) to find the hidden platform was decreased following the 4-d training sessions 
(F(3, 87) =6.455, P < 0.01). Significant main effects existed in group WT vs. APP/PS1 
(F (1, 33) =5.912, P < 0.05) and in group saline vs. DA5-CH treatment (F(1, 33) =4.833, P 
< 0.05) on escape latency. There was a significant interaction between APP/PS1 and 
DA5-CH treatment (F(1, 33) =5.213, P < 0.05). The mean escape latency of mice in the 
APP/PS1 model group on the training day 9 (40.87 ± 3.61 s, P < 0.01), and day 10 
(36.19 ± 3.63 s, P < 0.05) was significantly higher than that in the normal WT group 
(26.86 ± 3.38 s and 23.37 ± 3.40 s). However, DA5-CH decreased the escape latency 
in APP/PS1 mice on the day 8 (30.66 ± 4.52 s, P < 0.05), day 9 (28.03 ± 3.62 s, P < 
0.05), and day 10 (25.14 ± 3.64 s, P < 0.05), compared with the APP/PS1+Saline 
group. In the probe trials, two-way ANOVA showed that APP/PS1 and DA5-CH 
treatments had significant main effects on the percentage of swimming time in target 
quadrant (APP/PS1: F(1, 33) =11.154, P < 0.01; DA5-CH treatment: F(1, 33) =4.898, P < 
0.05; APP/PS1 by DA5-CH interaction: F(1, 33) =5.386, P < 0.05) and the number of 
platform crossings (APP/PS1: F(1, 33) =4.049, P < 0.05; DA5-CH treatment: F(1,33) 
=4.731, P < 0.05; APP/PS1 by DA5-CH interaction: F(1, 33) =6.466, P < 0.05). As 
shown in Fig. 4C, the significant decrease in the percentage of swimming time in 
target quadrant in the APP/PS1 mice (14.40 ± 1.60%, P < 0.001) compared with the 
WT mice (32.50 ± 4.40%) had an obvious recovery in the DA5 treated APP/PS1 mice 
(26.30 ± 2.30%, P < 0.05), compared with that in the APP/PS1+Saline group. 
Similarly, the decreased frequency of platform crossing (Fig. 4D) in APP/PS1+Saline 




mice (2.00 ± 0.45, P < 0.05). This indicates that chronic treatment with DA5-CH can 
alleviate the impairment in the relearning ability and cognitive flexibility of APP/PS1 
transgenic mice. 
 
3.5 DA5-CH effectively reversed the impairment of hippocampal synaptic 
plasticity in APP/PS1 transgenic mice. 
We further analyzed the effects of DA5-CH on the in vivo hippocampal L-LTP after 
behavioral tests. As shown in Fig. 5A, the average fEPSP slopes during 30 min of 
baseline recording under low frequency of test stimulation were stable in all groups. 
After delivering three sets of HFS to the hippocampal Schaffer collateral, the 
induction of LTP was successfully induced in all groups and there was no significant 
difference between groups. However, the 180-min recording of L-LTP showed that the 
hippocampal L-LTP of APP/PS1 transgenic mice was impaired and the treatment with 
DA5-CH could reverse this impairment effectively (F(3, 60) =13.104, P < 0.001). There 
were a significant main effect of APP/PS1 (F(1, 20) =6.733, P < 0.05) and DA5-CH 
treatment (F(1, 20) =4.951, P < 0.05) on 180-min recording of L-LTP and a significant 
interaction between APP/PS1 and DA5-CH treatment (F(1, 20) =5.102, P < 0.05). Fig. 
5B showed the percentage changes in fEPSP slopes at three time points after HFS. 
There was a significant decline in the maintenance of L-LTP at 60 min (119.10 ± 
11.90%, P < 0.05), 120 min (112.80 ± 10.80%, P < 0.05) and 180 min (112.30 ± 
11.50%, P < 0.05) after HFS in the APP/PS1 model group, compared with that in the 
control group (155.20 ± 12.00%, 155.30 ± 10.90% and 150.90 ± 11.60%, 
respectively). In contrast, in DA5-CH injected APP/PS1 transgenic mice, L-LTP was 
maintained at higher levels, being 153.30 ± 11.30%, 158.00 ± 10.20% and 150.70 ± 
11.30% (P < 0.05 for each one) at 60 min, 120 min and 180 min after HFS, 
respectively. The results indicate that DA5-CH could effectively reverse the 
impairment of hippocampal L-LTP in the APP/PS1 AD mice. 
In order to clarify the presynaptic or postsynaptic mechanism of DA5-CH affecting 




paired-pulse facilitation (PPF), a short term synaptic plasticity reflecting presynaptic 
neurotransmitter release. No significant difference in the facilitation of fEPSP was 
found between all groups (APP/PS1: F(1, 20) <1; DA5-CH treatment: F(1, 20) =1.055, P > 
0.05; APP/PS1 by DA5-CH interaction: F(1, 20) <1; Fig. 5D). The PPF ratio values 
were 149.85 ± 8.13%, 167.52 ± 13.81%, 151.56 ± 9.03%, and 154.44 ±7.85% in 
WT+Saline, WT+DA5-CH, APP/PS1+Saline, and APP/PS1+DA5-CH mice, 
respectively. This suggests that neither DA5-CH nor APP/PS1 gene expression had 
any effect on neurotransmitter release from presynaptic terminals, and the effects of 
DA5-CH and APP/PS1 genes on hippocampal L-LTP are mainly associated with 
postsynaptic changes.  
 
3.6 DA5-CH reduced hippocampal Aβ plaque load and tau phosphorylation in 
APP/PS1 mouse brains 
In immunofluorescence staining studies, we aimed to evaluate the histopathologic 
changes in hippocampus of mice. We observed and compared the Aβ plaque and 
neurofibrillary tangles of hippocampus among all groups. Two-way ANOVA showed 
that APP/PS1 and DA5-CH treatments had significant main effects on the Aβ plaque 
(APP/PS1: F(1, 12) =66.471, P < 0.001; DA5-CH treatment: F(1, 12) =60.085, P < 0.001; 
APP/PS1 by DA5-CH interaction: F(1, 12) =61.892, P < 0.001) and the neurofibrillary 
tangles of hippocampus (APP/PS1: F(1, 12) =45.710, P < 0.001; DA5-CH treatment: 
F(1, 12) =18.175, P < 0.01; APP/PS1 by DA5-CH interaction: F(1, 12) =9.868, P < 0.01). 
As shown in Fig. 6, there were few Aβ plaques in the hippocampal slices in the 
normal control group and DA5-CH alone group. In contrary, a large number of Aβ 
positive plaques was observed in the hippocampal slices of APP/PS1+Saline group 
(483.08 ± 65.03%, P < 0.001), significantly more than in the WT+Saline (100 ± 
9.45%). Importantly, the numbers of Aβ plaques had a significant reduction in the 
hippocampus of APP/PS1+DA5-CH group mice (109.83 ± 15.71%, P < 0.001) 
compared to that in the APP/PS1 model group. The Fig. 7 shows representative 
phosphorylated tau-positive cells in the hippocampus of mice. The positive staining of 




26.34%, P < 0.001) had a significantly increase compared to that in the normal WT 
mice (100 ± 16.78%), while it was strongly suppressed by the DA5-CH pretreatment 
in the APP/PS1+DA5-CH group (157.25 ± 35.25%, P < 0.001). These results 
demonstrate that nine-month-old APP/PS1 transgenic mice have shown distinct Aβ 
plaques and neurofibrillary tangles in the hippocampus and the treatment with 
DA5-CH can effectively reduce these pathological biomarkers. 
 
3.7 DA5-CH normalized the PI3K/AKT/GSK3β signaling activity in the 
hippocampus of APP/PS1 mice         
To further explore the probable molecular mechanism of DA5-CH in ameliorating the 
behavioral damage and pathological features in the APP/PS1 mice, we detected the 
expression levels of p-PI3K, p-AKT, and p-GSK3β in the hippocampus by 
Western-blot (Fig.8). We found that the relative protein expression of total 
PI3K/β-actin, total AKT/β-actin and total GSK3β/β-actin did not change in all groups 
(Fig.8 C, E, G). However, APP/PS1 and DA5-CH treatments had significant main 
effects on the levels of p-PI3K (APP/PS1: F(1, 20) =4.781, P < 0.05; DA5-CH 
treatment: F(1, 20) =6.339, P < 0.05; APP/PS1 by DA5-CH interaction: F(1, 20) =4.922, 
P < 0.05) and the levels of p-AKT (APP/PS1: F(1, 20) =7.564, P < 0.05; DA5-CH 
treatment: F(1, 20) =4.251, P < 0.05; APP/PS1 by DA5-CH interaction: F(1, 20) =5.284, 
P < 0.05) and the level of p-GSK3β (APP/PS1: F(1, 20) =10.528, P < 0.01; DA5-CH 
treatment: F(1, 20) =8.407, P < 0.05; APP/PS1 by DA5-CH interaction: F(1, 20) =9.820, 
P < 0.01). The levels of p-PI3K, p-AKT in APP/PS1+Saline group mice showed 
down-regulation (43.70 ± 8.40%, P < 0.05; 37.40 ± 9.00%, P < 0.05, respectively) , 
while the level of p-GSK3β (185.87 ± 14.86%, P < 0.05) showed up-regulation, 
compared to the values in the WT+Saline group. Importantly, compared with the 
APP/PS1+Saline group, the levels of the p-PI3K and p-AKT were increased (94.30 ± 
18.90%, P < 0.05; 96.40 ± 16.40%, P < 0.05, respectively), and the levels of 
p-GSK3β had been decreased (105.11 ± 10.01%, P < 0.05) in the group of APP/PS1 








The earliest manifestation of AD is the deficit of working memory, which gradually 
develops into impairments in reference memory and general cognitive function, and 
eventually severe dementia (Selkoe, 2001). At present, the standard treatment for AD 
is the use of cholinesterase inhibitors or NMDA receptor blockers to improve the 
cognitive behavior of patients. However, apart from their side effects, these drugs can 
not fundamentally stop the disease progression of AD. We therefore tested the 
GLP-1/GIP dual agonist DA5-CH in nine-month-old APP/PS1 AD mice.  
The results of behavioral tests showed that the APP/PS1 mice had a significant 
decrease in the percentage of spontaneous alternation in Y maze, a increase in the 
escape latency in underwater platform searching, and a significant decrease in the 
swimming time or platform crossing in the target quadrant; while the total running 
distance, total arm entries and average swimming speed in the AD mice were 
basically normal. These results indicated that the APP/PS1 mice displayed excellent 
behavioral phenotypes including working memory and long term spatial memory 
impairments. Moreover, the APP/PS1 mice also exhibited a decline in the cognitive 
flexibility in reversal MWM test. Importantly, we confirmed for the first time that 
chronic intraperitoneal injection of GLP-1/GIP dual agonist DA5-CH effectively 
improved the working memory and long-term memory in the APP/PS1 mice. This is 
in line with the results we have reported before, that the GLP-1 analogue Liraglutide 
prevents the decline of spatial memory, the deficits of hippocampal LTP, chronic 
inflammation and loss of synapses in APP/PS1 mice (McClean et al., 2011; McClean 
and Holscher, 2014a; McClean et al., 2015) or amyloid-infused rats (Qi et al., 2016), 
and that the GLP-1 analog Lixisenatide also reduces amyloid plaque load, memory 
and LTP impairments, and synapse loss and chronic inflammation in the APP/PS1 




induced neuronal impairment and improves spatial memory (Cai et al., 2017). Besides, 
Velmurugan et al. found the neuroprotection of GLP-1 analogues in differentiated 
human neuroprogenitor cells (Velmurugan et al., 2012). When analyzing GIP 
analogues, D-Ala
2
-GIP also protects memory formation, LTP induction, and increases 
the number of synapses in the brain and reduces Aβ plaque deposition while reducing 
chronic inflammation in APP/PS1 mice (Duffy and Holscher, 2013; Faivre and 
Holscher, 2013a, b). As for the role of GLP-1/GIP dual agonist on memory disorders, 
Shi et al. have shown the potential neuroprotective effect of dual GLP-1/GIP receptor 
agonist (DA-JC4) in the i.c.v. streptozotocin (STZ)-induced AD rat model, and they 
found that treatment with DA-JC4 significantly prevented working memory and long 
term spatial memory impairments in Y-maze test and Morris water maze tests (Shi et 
al., 2017a). This is in line with the results in the present study that chronic 
intraperitoneal injection of GLP-1/GIP dual agonist DA5-CH effectively improved the 
working memory and long-term memory in the APP/PS1 mice. These results suggest 
that a dual GLP-1/GIP receptor agonist such as DA5-CH may have disease modifying 
properties in AD patients. The probability is still to be confirmed by further clinical 
trials in the future. 
It has been certified that the spatial learning and memory in animals are encoded by 
alteration or modulation of synaptic strength in the hippocampus (Clements et al., 
1993). The hippocampal LTP, a persistent increase in postsynaptic reaction induced by 
HFS, has been thought as a primary cellular mechanisms determining learning and 
memory (Clements et al., 1993; Cooke and Bliss, 2006). It is well known that 
different types of stimulation can induce different strength of hippocampal LTP. In the 
present study, three sets of HFSs were applied to induce the long-lasting late phase of 
LTP, in which the enhanced synaptic transmission was kept at least for 180 min. The 
long-lasting LTP is dependent on cAMP-dependent protein kinase activity (PKA) and 
de novo gene expression, and the synthesis of new synaptic protein (Impey S et al., 
1996). Thus, L-LTP may be the electrophysiological basis affecting long term 




not affect the basic synaptic transmission, but treatment with DA5-CH could 
significantly prevent the hippocampal L-LTP deficit in the APP/PS1 AD mice. The 
protective effect of DA5-CH on L-LTP might well explain the behavioral 
improvements of APP/PS1 transgenic mice in the successive 5 days of MWM test. It 
is reported that AD mouse model has significant decrease in dendritic spines density 
in hippocampal neurons (Chen et al., 2014); Aβ overproduction also affected dendritic 
spine morphology in the hippocampus (Knafo et al., 2009; Merino-Serrais et al., 
2011); GLP-1 improved synaptic plasticity and structural plasticity (i.e., dynamics of 
dendritic spines) (Mainardi et al., 2015). Further, over excitation of NMDA receptors 
led to excessive Ca
2+
 influx through receptor-associated ion channels, resulting in 
neuronal cell injury or death (Folch et al., 2017); our previous study also showed that 
Exendin-4, a GLP-1 analog used for T2DM treatment, significantly antagonized 
Aβ1-42-induced LTP suppression and [Ca2+]i elevation through VDCCs and 
NMDARs (Wang et al., 2015). Therefore, we suppose that the alteration of 
hippocampal dendritic spines and NMDARs might be implicated in the impairments 
of LTP and cognitive behavior in the AD mice in the present study, while the 
improvement of cognitive behavior and synaptic plasticity by DA5-CH could be 
associated with the modification of synaptic morphology and the regulation of 
NMDARs. 
In addition to the gathering of Aβ, another typical pathological features of AD is 
neurofibrillary tangles formed by excessive phosphorylated tau (p-tau) protein 
aggregation (Rönicke et al., 2011). Our experimental results demonstrated that the 
immunopositive staining of Aβ and phosphorylated tau in the hippocampus of 
APP/PS1 transgenic mice was significantly increased compared to WT mice, while 
DA5-CH treatment distinctively ameliorated the aggregation of Aβ plaques and 
excessive phosphorylation of tau protein. A previous study also showed a reduction of 
tau phosphorylation in a transgenic mouse model by treatment with liraglutide 
(Hansen et al., 2016). These changes may also account for the improvement of 




as a critical event in AD pathology (Lim et al., 2015). Reactive microglia and 
astrocytes adjacent to Aβ core consist of inflammatory plaques with Aβ in the AD 
brain (Itagaki et al., 1989). Chronic inflammation leads to the production of several 
cytokines that have been demonstrated to exacerbate other AD pathologies (Kitazawa 
et al., 2004). Aβ-induced down-regulation of PI3K/AKT lead to excessive activation 
of GSK3β, which accelerating the gene expression of the inflammatory factors such as 
TNF-α，triggering the inflammatory reaction in the brain and exacerbating the AD's 
condition (Phoon et al., 2016). Previously, we have shown that the GLP-1 analogue 
Liraglutide prevents the chronic inflammation and loss of synapses in APP/PS1 mice 
(McClean et al., 2011; McClean and Holscher, 2014a; McClean et al., 2015) or 
amyloid-infused rats (Qi et al., 2016), and that the GLP-1 analogue Lixisenatide also 
reduces amyloid plaque load and chronic inflammation in the APP/PS1 mouse model 
(McClean and Holscher, 2014b). Further, the neuroprotection of DA-JC1, a 
GLP-1/GIP dual agonist similar to DA5-CH, has been reported by reducing chronic 
inflammation in the brain (Cao et al., 2016b). Thus, considering the close association 
between inflammation and Aβ or PI3K/AKT/GSK3β signals, it is reasonable to 
assume that anti-inflammation effect might contribute positively to the 
neuroprotection of DA5-CH. 
The alterations in cerebral pathological features and cognitive behaviors in the AD 
model mice may reflect changes in the signaling pathways in the brain. GSK3β is one 
of the kinases that phosphorylates tau protein. This kinase is involved in the 
regulation of cellular processes (Farris et al., 2003; Gasparini et al., 2001). 
Over-expression of GSK3β in transgenic drosophila brains significantly elevated the 
phosphorylation level of tau protein (Leissring, 2003). GSK3β is activated by the 
phosphorylation of tyrosine at 216. PI3K/AKT signaling is an important pathway for 
regulating GSK3β. When activated by the cell surface receptor, PI3K phosphorylates 
downstream AKT. The activated AKT inhibits the phosphorylation of 216 tyrosine of 
GSK3β, thereby inhibiting the activity of GSK3β protein (Kitagishi et al., 2012). In 




unbalanced PI3K/AKT/ GSK3β activity in the APP/PS1 mice. DA5-CH treatment not 
only decreased the pathological biomarks, but also normalized the unbalanced 
PI3K/AKT/GSK3β levels. It's noteworthy that the mice used in the signal pathway 
experiment were just the animals after experiencing behavioral and electrophysiologic 
experiments. The changes in different physiological indexes on the same mice may 
reflect their close correlation and contribution in the study. In fact, the molecular 
mechanism of AD involves multiple signaling pathways such as PI3K/AKT/GSK3β, 
Ras/MAPK-ERK, PKA/CREB etc (Cuellar and Isokawa, 2011; Frago et al., 2011; 
Mainardi et al., 2015). We speculate that Aβ-induced down-regulation of PI3K/AKT 
lead to excessive activation of GSK3β, by which accelerating the phosphorylation of 
tau protein, the degradation of microtubule in neurons, and the impairment of synaptic 
plasticity and memory formation. In contrast, DA5-CH can prevent the excessive 
activation of GSK3β by up-regulating the PI3K/AKT signaling, thus protecting 
memory and improving the pathological changes in the AD transgenic mice. A 
previous study showed that the dual agonist DA4-JC improved insulin signaling in the 
i.c.v. STZ rat model of AD (Shi et al., 2017b). APP/PS1 mice show insulin 
desensitization that can be reversed by GLP-1 analogues (Long-Smith et al., 2013), 
and the normalization of insulin signaling could be the reason for the normalization of 
PI3K/AKT signaling. Previously, we have shown the such dual agonists have 
protective effects in animal models of Parkinson (Cao et al., 2016a; Hölscher, 2016; 
Jalewa et al., 2017; Ji et al., 2016; Yuan et al., 2017), and stroke (Han et al., 2016), 
demonstrating the great potential that such dual receptor agonists show. It is 
interesting that the neuroprotection of DA5-CH treatment achieves almost-complete 
reverse effect on the behaviors or the pathologies, while it can only partially 
ameliorate the PI3K/AKT/GSK3β signaling pathway. This result may suggest that not 
only PI3K/AKT/GSK3β but also other signaling pathways such as Ras/MAPK-ERK, 
PKA/CREB are involved in the neuroprotection mechanism of DA5-CH (Cuellar and 
Isokawa, 2011; Frago et al., 2011; Mainardi et al., 2015). Therefore, to be sure, there 




In summary, the present study confirmed for the first time the neuroprotective roles of 
the novel GLP-1/GIP dual agonist DA5-CH on the cognitive impairments and 
neuropathological processes in APP/PS1 transgenic AD mice. The neuroprotection of 
DA5-CH was associated with the improvement of hippocampal synaptic plasticity and 
PI3K/AKT/GSK3β signaling pathway. Therefore, this study provides a novel and 
promising strategy to treat neurodegenerative disease such as AD. 
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Fig. 1. DA5-CH did not affect the locomotor and exploratory performance of 
APP/PS1 and WT mice. (A and B), Histograms showing the total running distance in 
the open field (A) and running time spent in the central area (B) of mice in 5 min, 
without any significant difference between the four groups (P>0.05, n＝8-14). Each 
column represents the mean ± S.E.M. 
Fig. 2. DA5-CH improved working memory of APP/PS1 mice in the Y-maze. (A), 
Total arm entries of mice in 8 min, without any significant difference between the four 
groups (P>0.05, n＝8-14). (B), The percentage of correct spontaneous alternation of 
mice, with a decrease only in the mice of APP/PS1+Saline group (*** P<0.001 , n＝
8-14). Each column represents the mean ± S.E.M. 
Fig. 3. DA5-CH ameliorated the deficits in spatial learning and memory of APP/PS1 
mice in the WM test. (A and B), Average escape latencies of mice in acquisition trial 
phase from training day 1 to day 5. *P<0.05, **P<0.01. (C and D), Percentage of 
swimming time in target quadrant (C) and frequency of platform crossing (D) in the 
probe trial phase on the sixth day. *P<0.05, **P<0.01. All values were displayed as 
mean ± S.E.M (n＝8-14). (E), Representative swimming tracks of mice in different 
groups in the probe trials. The black dots indicate the starting points placing the mice 
into the pool. The small open circles indicate the previous location of platform. 
Fig. 4. DA5-CH improved relearning and the cognitive flexibility of APP/PS1 mice. 
(A and B), Average escape latencies of mice in acquisition trial phase from training 
day 7 to 10. *P<0.05, **P<0.01. (C and D), Percentage of time in target quadrant (C) 
and frequency of platform crossing (D) in the probe trial phase on the training day 11. 
*P<0.05, ***P<0.001. All values were displayed as mean ± S.E.M (n＝8-14). (E), 
Representative swimming tracks of mice in the probe trials. Note that the platform 
(small open circles) had been shifted to the opposite quadrant. 
Fig. 5. DA5-CH effectively reversed the impairment of hippocampal L-LTP in 
APP/PS1 transgenic mice. (A), Scatter plots showing the changes of fEPSP slope in 
different groups. After application of three sets of HFS, LTP was successfully induced 
in all groups, but the maintenance of LTP, especially the L-LTP at 180 min after HFS, 




fEPSPs slope values in four groups at different time points before and after HFSs. 
Each column indicates the mean ± S.E.M. of fEPSPs slope. *P<0.05 (n＝6). (C), 
Representative fEPSP traces before (black) and 180 min after (red) HFS. (D), 
Histograms showing the PPF change percentage in all groups, without any significant 
differences between groups. Inserts: a representative PPF trace recorded before HFS. 
Fig. 6. DA5-CH reduced hippocampal Aβ plaque loads in the brain of APP/PS1 mice. 
(A), The immunofluorescence micrographs showing the hippocampal Aβ plaques in 
four groups of mice. The immunofluorescent red stains are Aβ-positive plaques 
recognized by the 6E10 antibody. The blue shows nuclei (DAPI). Scale bar = 100 μm 
(top) and 50 μm (bottom). (B), Aβ plaque levels. All data are expressed as the 
percentage of control values. ***P<0.001 (n＝4) 
Fig. 7. DA5-CH reduced hippocampal p-tau levels in APP/PS1 mouse brains. (A), 
The immunofluorescence micrographs showing hippocampal p-tau (red) recognized 
by the AT8 antibody, and nuclei in blue (DAPI). Scale bar = 100 μm (top) and 50 μm 
(bottom). (B), Quantitative analysis of p-tau levels. All data are expressed as the 
percentage of control values. ***P<0.001 (n＝4). 
Fig. 8. Western blot quantitative analysis for the PI3K-AKT-GSK3β signaling 
pathway in the hippocampus of all groups. (A), Representative Western blot scan 
showing the expression levels of p-PI3K, t-PI3K, p-AKT, t-AKT, p-GSK3β and t- 
GSK3β in different groups. (B, C, D, E, F and G), Quantitative analysis of levels. All 
data are expressed as the percentage of control values. *P<0.05 (n＝6) 
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